Patients with late-stage cancers should gain more rapid access to innovative treatments through the National Health Service under plans unveiled by the government on Tuesday.

In a blueprint concluding months of consultations with industry, the Office for Life Sciences earmarked an initial £25m ($41m) next year for a pilot programme to fund experimental drugs for patients with rare illnesses ahead of the usual approval from the government’s medicines advisory body before their use in the NHS.